

Lucas Mayol M José, Guillén Martínez O, Castejón Grao I, Morante Hernández M, Murcia López AC, Navarro Ruiz A.
Hospital General Universitario de Elche, Pharmacy Department

BACKGROUND AND IMPORTANCE

Ustekinumab is a monoclonal antibody used in inflammatory diseases like Crohn's disease (CD) and ulcerative colitis (UC).

AIM AND OBJECTIVES

To know the **dosage** usually used in our patients compared to that indicated in the label, and the **economic impact** when an intensified dosage is used.

MATERIAL AND METHODS



Retrospective observational study (January 2022-March 2023)



Patients with inflammatory bowel disease (IBD) treated with Ustekinumab.



Software used: Orion Clinic®, FarmisOncofarm® y Orion Logis.

Variables collected

Sex	Age
Weight	Indication
Dosage (induction and maintenance)	Economic data


RESULTS




N = 39 patients

59% men and 41% women
Mean age: 54 years
Average weight: 67 kg


Indication




Intravenous induction regimen



Maintenance regimen



*The maintenance regimen established in the label is 90mg sc/ 8 weeks



Average **cost** of the treatment

❖ Dosage of the label → 20.148€
❖ Intensified dosage → 38.533€

CONCLUSIONS

In half of the patients, the maintenance dosage was off-label, requiring changes in both the dosage regimen and the route of administration to achieve the clinical objectives, highlighting the need of individualization. In addition, the intensification dosage involves a financial cost of almost twice as much.

